Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials
© Springer Nature Switzerland AG 2020..
The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
---|---|
Enthalten in: |
SN comprehensive clinical medicine - 2(2020), 8 vom: 10., Seite 1120-1131 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Siordia, Juan A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Arbidol |
---|
Anmerkungen: |
Date Revised 18.02.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1007/s42399-020-00399-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314116141 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314116141 | ||
003 | DE-627 | ||
005 | 20231225152037.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s42399-020-00399-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1047.xml |
035 | |a (DE-627)NLM314116141 | ||
035 | |a (NLM)32838169 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Siordia, Juan A |c Jr |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 18.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © Springer Nature Switzerland AG 2020. | ||
520 | |a The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Arbidol | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a Dexamethasone | |
650 | 4 | |a Favipiravir | |
650 | 4 | |a Heparin | |
650 | 4 | |a Hydroxychloroquine | |
650 | 4 | |a Lopinavir/ritonavir | |
650 | 4 | |a Remdesivir | |
650 | 4 | |a SARS-CoV2 | |
650 | 4 | |a Tocilizumab | |
650 | 4 | |a Treatment | |
650 | 4 | |a Trials | |
700 | 1 | |a Bernaba, Michael |e verfasserin |4 aut | |
700 | 1 | |a Yoshino, Kenji |e verfasserin |4 aut | |
700 | 1 | |a Ulhaque, Abid |e verfasserin |4 aut | |
700 | 1 | |a Kumar, Sooraj |e verfasserin |4 aut | |
700 | 1 | |a Bernaba, Mario |e verfasserin |4 aut | |
700 | 1 | |a Bergin, Edward |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d 2019 |g 2(2020), 8 vom: 10., Seite 1120-1131 |w (DE-627)NLM300071965 |x 2523-8973 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2020 |g number:8 |g day:10 |g pages:1120-1131 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s42399-020-00399-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 2 |j 2020 |e 8 |b 10 |h 1120-1131 |